Globeflex Capital’s Amicus Therapeutics FOLD Stock Holding History

Globeflex Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-86,878	Closed	-$1.24M	–	423
2025 Q4	$1.24M	Buy	+86,878	New	+$853K	0.19%	133

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Globeflex Capital's FOLD Position: Q1 2026 in Review

Globeflex Capital sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 86,878 shares — an estimated $1.24M sold.

Globeflex Capital first reported a position in FOLD in Q4 2025 and held it in 1 quarter. The position peaked at $1.24M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Globeflex Capital reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Globeflex Capital sold 86,878 Amicus Therapeutics shares in Q1 2026, an estimated $1.24M.
Globeflex Capital first reported a position in Amicus Therapeutics in Q4 2025 and held it in 1 quarter.
Globeflex Capital's Amicus Therapeutics position peaked at $1.24M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Globeflex Capital's 13F filing for Q1 2026, filed 13 May 2026.